Phase 3 ARANOTE Study of ADT + Darolutamide

Opinion
Video

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the efficacy of this combination therapy in a patient population with newly diagnosed mHSPC. He compares its design and objectives with other established ADT plus androgen receptor pathway inhibitor (ARPI) doublet regimens such as LATITUDE, STAMPEDE D, ENZAMET, ARCHES, and TITAN, and how the study’s results, particularly its efficacy data, compare with those from other trials using abiraterone, enzalutamide, and apalutamide in the first-line setting.

Video content above is prompted by the following:

  1. Please discuss the design, population, and objectives of the ARANOTE study of ADT plus+ darolutamide for mHSPC. How do the study’s design and population compare with those of other established ADT + plus ARPI doublet regimens (ie, LATITUDE, STAMPEDE D, ENZAMET, ARCHES, TITAN)?
  2. Please review the efficacy data from ARANOTE. How do the results compare with those of other ADT plus + ARPI combination regimens available as 1L first-line therapy for mHSPC?
    1. ARANOTE (ADT + darolutamide [DARO])
      1. Which efficacy data points from this study stand out to you
    2. LATITUDE/STAMPEDE-G (ADT + abiraterone [ABI]/prednisone)
    3. ENZAMET/ARCHES (ADT + enzalutamide [ENZA])
    4. TITAN (ADT + apalutamide [APA])
Recent Videos
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content